Insight

Pharmaceuticals

~THB 280B market; GPO state, MEGA, TNP, Siam Pharma, MNC originator subsidiaries (GSK / Pfizer / Novartis / Roche)

Last updated: Live coverage

Reports in this sector

5

Market profiles

12

Cited sources

73

Primary-grade share

71%

Key statistics

Public reference figures, each linked to source-level context.

FY2024
~THB 250B

Thai pharmaceutical market size

PReMA, TPMA, FDA Thailand, IQVIA

FY2024
~70%

Pharma imports share

FDA Thailand, UN Comtrade HS 30

FY2024
~10-15%

GPO (Government Pharma Organisation) share

GPO annual report, NHSO

FY2024
~THB 60B

UCS (Universal Coverage Scheme) drug expenditure

NHSO budget, MOPH

FY2024
~THB 40B combined

Listed pharma distributor revenue (Mega, DCC)

MEGA, DCC 56-1 FY2024

Market profiles in this sector

12 free profiles tied to reports, filings, regulations, and source-backed context.

Browse Market Atlas →
Government

Government Pharmaceutical Organisation (GPO)

Thai state pharmaceutical manufacturer; generics, HIV ARV, biosimilar, Strategic Stockpile; FY2024 revenue ~THB 16B.

5 reports
Government

Government Pharmaceutical Organization (GPO)

Thai state pharmaceutical manufacturer; produces essential medicines, vaccines, and APIs under MoPH mandate for public-health security.

6 reports
Company/operator

GSK Thailand

UK-parent MNC originator Thai subsidiary; respiratory, vaccines, HIV, oncology; ~8% Thai market value share.

2 reports
Company/operator
SET:MEGA

Mega Lifesciences

Largest Thai-listed pharma by revenue; emerging-market distribution franchise; FY2024 revenue ~THB 16B.

5 reports
Company/operator

Novartis Thailand

Swiss-parent MNC specialty Thai subsidiary; oncology, cardiovascular, biosimilar; ~6% Thai market value share.

3 reports
Company/operator

Pfizer Thailand

US-parent MNC originator Thai subsidiary; oncology, primary care, vaccines; ~7% Thai market value share.

2 reports
Company/operator

Roche Thailand

Swiss-parent MNC specialty Thai subsidiary; oncology, biologics, diagnostics; ~5% Thai market value share.

3 reports
Company/operator

Siam Pharmaceutical

Leading private Thai generics, OTC manufacturer since 1939; hospital, retail, wholesale channel depth.

5 reports
Company/operator

Thai Domestic Generic Pharma Cluster (Berlin, Siam Pharm, MEGA Lifesciences)

Cluster of Thai domestic generic pharmaceutical manufacturers producing off-patent medicines for domestic distribution and ASEAN export.

1 report
Company/operator

Thai MNC Pharma Channel (GSK, Pfizer, Novartis, Roche)

Cluster of multinational originator pharma subsidiaries operating in Thailand, distributing branded innovative drugs through hospital and specialist channels.

1 report
Company/operator
SET:TNP

Thai Nakorn Patana

Listed Thai generics, OTC, hospital products; FY2024 revenue ~THB 3B; domestic focus.

2 reports
Company/operator

Thai Pharma Wholesale Channel (DKSH, Zuellig Pharma, Sino Pacific)

Cluster of specialist pharmaceutical wholesale and distribution operators linking manufacturers to hospitals, clinics, and pharmacies across Thailand.

1 report

Available reports

Thailand Diabetes, Insulin, Chronic Disease Pharma Deep Dive

Thai diabetes pharma ~THB 30-40B. ~5-6M Thai diabetic, ~1.5-2M on insulin. Novo Nordisk, Sanofi, Lilly, GLP-1, Thai generic GPO, Siam Pharm. NLEM, UC coverage.

Thailand Life Sciences, Biotech, GPO BioPharm Deep Dive

GPO, Siam Bioscience, Bumrungrad/BDMS clinical-trial sites, Mahidol/Chula research; biosimilar, vaccine, cell-therapy, CRO, EEC Genomics Thailand investment.

Thailand Pharma Generic vs Branded Deep Dive

Thai pharma ~THB 250B. Generic ~60% vol / ~30% value; branded ~40% vol / ~65% value; biosimilar emerging. SPC, Mega, GPO, Siam Bioscience vs Pfizer, Novartis, Roche MNC.

The Thai Pharma Import Lane: Multinational Brands, Thai-FDA Pathway, and Generic Substitution

Thai pharma market estimated THB 220-280B annual; ~60% pharma-branded import (Pfizer, Sanofi, Novartis, Roche, Bayer, Boehringer Ingelheim, AstraZeneca), ~40% Thai-domestic generic (GPO, Siam Bioscience, Berlin Pharmaceutical, Thai Otsuka, Olic). Thai FDA Drug Act 1967 (revised) approval pathway; multinational, Thai-licensee distribution model standard. NLEM National List of Essential Medicines drives public-procurement substitution. CL (Compulsory Licensing) precedent 2007-2008 for HIV ARVs.

Thailand Pharmaceuticals Market Intelligence

Thailand's pharmaceuticals market is a ~THB 280B platform: 50% imported originators (GSK, Pfizer, Novartis, Roche Thai subs), 25% imported generics, 20% domestic generics (GPO, Mega, Siam Pharma, TNP), 5% OTC. UCS, SSS, CSMBS payer framework, NLEM pricing drive access.

More sectors in Healthcare & Life Sciences

Medical Devices

View sector →

Beauty OEM & ODM

View sector →

Hospitals & Medical Tourism

View sector →

Wellness & Spa Industry

View sector →

Elder Care & Assisted Living

View sector →

Medical Cannabis & CBD Products

View sector →

Full sector report

The Thai Pharma Import Lane: Multinational Brands, Thai-FDA Pathway, and Generic Substitution

18 min read · 2026 Edition

Preview report·$99
Pharmaceuticals · Insight